In adult ICU patients with persistent delirium, should ketamine be used as a treatment?

Ketamine Should Not Be Used to Treat Persistent Delirium in ICU Patients

Do not use ketamine to treat persistent delirium in adult ICU patients. The established clinical practice guidelines make no recommendation for ketamine in delirium treatment, and the FDA-approved indication for ketamine is solely for anesthesia induction and maintenance, not delirium management 1, 2.

Guideline-Based Approach to ICU Delirium Treatment

The 2013 and 2018 Critical Care Medicine guidelines provide clear direction for managing persistent delirium 1, 3:

For persistent delirium unrelated to alcohol or benzodiazepine withdrawal:

• Switch sedation to dexmedetomidine rather than continuing benzodiazepine infusions (Grade 2B recommendation) 1
• This is the only pharmacologic intervention with a positive recommendation for reducing delirium duration

Pharmacologic agents NOT recommended for delirium treatment:

• Haloperidol: No published evidence it reduces delirium duration 1, 3
• Atypical antipsychotics (quetiapine, ziprasidone, olanzapine): Only weak evidence (Grade C) suggesting possible benefit 1, 3
• Rivastigmine: Actively recommended against (Grade -1B) 1
• Statins: Not recommended for treatment 3

Why Ketamine Is Not Appropriate for Persistent Delirium

Lack of Evidence for Treatment

The 2018 guidelines explicitly state that no evidence exists for using NMDA receptor antagonists (including ketamine) to treat established delirium 3. One large RCT found that perioperative ketamine did not decrease delirium in older adults after major surgery 3.

Conflicting Research Evidence

While some retrospective studies suggest ketamine may reduce delirium incidence when used preventively during anesthesia 4, 5, 6, the evidence for treating existing persistent delirium is contradictory:

• A 2021 cohort study found ketamine analgosedation was independently associated with increased delirium risk (adjusted OR 5.60,95% CI 1.09-29.15) 7
• The 2018 RCT showed low-dose ketamine reduced delirium incidence and duration when used preventively, but this was in patients without established delirium 4
• Recent meta-analyses show inconsistent results, with 60% of studies showing no cognitive benefit 8

FDA-Approved Indication Does Not Include Delirium

Ketamine is FDA-approved only for anesthesia induction and maintenance 2. The label explicitly warns about:

• Emergence delirium and neuropsychological manifestations requiring benzodiazepine co-administration 2
• Psychotomimetic effects at higher doses 2
• No mention of therapeutic use for treating delirium

Neuropsychiatric Adverse Effects

Ketamine carries significant risks that are particularly problematic in delirious patients:

• Increased neuropsychiatric adverse events including hallucinations and nightmares (OR 1.60,95% CI 1.15-2.21) 9
• Emergence delirium requiring benzodiazepine prophylaxis 2
• Potential to worsen confusion in already delirious patients

Recommended Algorithm for Persistent ICU Delirium

Step 1: Address modifiable risk factors

• Discontinue or minimize benzodiazepines (major risk factor) 1
• Optimize opioid dosing (conflicting data on delirium risk) 1
• Implement early mobilization 1
• Optimize sleep environment (control light/noise, cluster care activities) 1

Step 2: If sedation is required

• Switch to dexmedetomidine infusion if currently on benzodiazepines 1
• Use daily sedation interruption or light sedation targets 1
• Employ analgesia-first sedation strategy 1

Step 3: Consider atypical antipsychotics cautiously

• May reduce delirium duration (weak evidence, Grade C) 1
• Avoid in patients with QTc prolongation risk or history of torsades de pointes 1
• Not routinely recommended but may be considered in refractory cases 3

Step 4: Do NOT use

• Haloperidol for delirium treatment (no evidence of benefit) 1, 3
• Rivastigmine (actively harmful) 1
• Ketamine (no evidence for treatment, potential to worsen delirium) 3, 7

Critical Caveats

Prevention vs. Treatment: The distinction is crucial. Some evidence suggests low-dose ketamine (0.25-0.34 mg/kg cumulative intraoperative dose) may reduce delirium incidence when used preventively during surgery 6. However, this does not translate to treating established persistent delirium in ICU patients.

Dose-Response Relationship: Research shows a U-shaped curve where very low doses may be protective but higher doses offer no benefit or potential harm 6. In ICU patients with established delirium, there is no established therapeutic dose.

Population Differences: Most positive ketamine studies involved surgical patients receiving single perioperative doses, not critically ill medical ICU patients with persistent delirium requiring ongoing treatment 9, 5, 8.

The evidence is clear: focus on non-pharmacologic interventions, optimize sedation with dexmedetomidine, and avoid adding ketamine to patients with established persistent delirium.